(lp0
S'The Medicines Company and Alnylam Pharmaceuticals Report Positive Final ... Yahoo Finance - Mar 17, 2017 The Medicines Company  and Alnylam Pharmaceuticals, Inc.  today announced positive final results from the ORION-1 Phase II study of inclisiran, an investigational, first-in-class PCSK9 synthesis inhibitor being developed for the treatment ...LDL-C Plunges on Novel Anti-PCSK9 Agent Inclisiran: ORION-1 - MedscapeACC: Novel Drug Delivers Long-Term Cholesterol Reduction - MedPage Today'
p1
aS"The Medicines Company to Host Conference Call and Webcast at Upcoming American ... Yahoo Finance - Mar 6, 2017 The Medicines Company  will host a conference call and webcast on Friday, March 17, 2017, at 3:30 p.m., Eastern Time, to review data from the ORION-1 Phase II study of inclisiran, the Company's PCSK9 synthesis inhibitor."
p2
aS'Earnings Reaction History: The Medicines Company, 44.4% Follow-Through ... Nasdaq - Feb 28, 2017 The Medicines Company  is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect light trading in the issue immediately following its quarterly earnings announcement.'
p3
aS"The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of ... Business Wire  - Mar 14, 2017 PARSIPPANY, N.J.----The Medicines Company  today announced that it will webcast, over the internet simultaneously with the presentation, the detailed results from its ORION-1 Phase II study of inclisiran, the Company's&nbsp;..."
p4
aS'The Medicines Company Partnering Deals and Alliances 2010 to 2017 PR Newswire  - Feb 27, 2017 Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top companies partnering with the company since 2010. Chapter 3 provides an overview of the leading partnering and M&amp;A deals since 2010 to present date based on headline value.'
p5
aS'The Medicines Company  Moves Lower on Volume Spike for March 17 Equities.com - Mar 17, 2017 The Medicines Company  traded on unusually high volume on Mar. 17, as the stock lost 7.99% to close at $48.38. On the day, The Medicines Company saw 20.39 million shares trade hands on 108,093 trades. Considering that the stock averages&nbsp;...Most Active Stock Update: The Medicines Company  - HugoPress'
p6
aS'The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results Yahoo Finance - Feb 28, 2017 Driven by strong execution against our strategic priorities, 2016 was a transformative year for the Company, said Clive Meanwell, M.D.'
p7
aS"The Medicines Company Announces FDA Filing Acceptance of New Drug Application ... Yahoo Finance - Feb 21, 2017 The Medicines Company  today announced that the U.S. Food and Drug Administration  has accepted for priority review the Company's new drug application  filing for Carbavance  for the treatment of&nbsp;...Carbavance Gets Priority Review for Complicated UTI - Monthly Prescribing Reference "
p8
aS"How Does the Chart Look for The Medicines Company  ? The USA Commerce - Mar 20, 2017 We have gathered the technical data on The Medicines Company , and see some interesting trends in the stock's behavior of late."
p9
aS"Hot Stock to Watch: The Medicines Company  HugoPress - Mar 21, 2017 H.C. Wainwright Initiates Coverage On The Medicines Company 's stock to Buy with the price target of $57. This rating was issued on 12/05/16.HC Wainwright Reiterates Buy Rating for The Medicines Company  - The Cerbat GemThe Medicines Company  Moves Higher on Volume Spike for March 20 - Equities.com"
p10
a.